Cargando…

Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion

The aim of this study was to evaluate the efficacy and adverse effects of lenalidomide in the treatment of intermediate-1 risk non-5q deletion [non-del (5q)] myelodysplastic syndrome (MDS). A total of 30 patients with MDS were classified through G-banding chromosome karyotype analysis and fluorescen...

Descripción completa

Detalles Bibliográficos
Autores principales:	YANG, YAN, GAO, SUJUN, FAN, HONGQIONG, LIN, HAI, LI, WEI, WANG, JUAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786804/ https://www.ncbi.nlm.nih.gov/pubmed/24137269 http://dx.doi.org/10.3892/etm.2013.1218

Ejemplares similares

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis
por: Lian, Xin-yue, et al.
Publicado: (2016)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
por: Lee, Dawn, et al.
Publicado: (2018)

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
por: Uno, Shuji, et al.
Publicado: (2023)

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Koh, Yu Han, et al.
Publicado: (2023)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
por: Hecht, Anna, et al.
Publicado: (2021)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
por: Jana, Bagi, et al.
Publicado: (2014)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Part 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion
por: Velloso, Elvira Deolinda Rodrigues Pereira, et al.
Publicado: (2018)

Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
por: Oliva, Esther N., et al.
Publicado: (2015)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

5q Deletion Myelodysplastic Syndrome in a Young Male Patient
por: Elkattawy, Sherif, et al.
Publicado: (2021)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
por: Washington, Nyomi R, et al.
Publicado: (2021)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

Part 4: Myelodysplastic syndromes—Treatment of low-risk patients with the 5q deletion
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018)

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
por: Feurstein, Simone, et al.
Publicado: (2018)

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
por: Kenealy, Melita, et al.
Publicado: (2019)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
por: Ades, Lionel, et al.
Publicado: (2017)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review
por: Zhao, Meifang, et al.
Publicado: (2021)

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
por: Park, Isaac, et al.
Publicado: (2021)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6u02o6cptauuunrercknjb0uu5